



National Hepatitis Control Program (NHCP)

2017 July



Vision: To free from viral hepatitis by halting transmission while those living with hepatitis has access to safe, affordable and effective treatment

Goal: To work within a health system framework and use effective public health approach within the premises of Universal Health Coverage

Target: Reduce incidence of viral hepatitis
Reduce mother to child transmission of HBV
Reduce the mortality due to viral hepatitis
Reduce the socioeconomic impact of viral hepatitis at individual, community and population levels

Framework for action: Universal Health Coverage, Continuum of Care and Public Health Approach

The Global Goal –
“To Eliminate Viral Hepatitis as Public Health Threat by 2030”



Indicator 3.3_
“Combat Hepatitis”

WORLD
HEPATITIS DAY
28th July



Hepatitis
is present
worldwide*



Hepatitis is present worldwide*

It can be serious
and even fatal
but it is
preventable!

May 2010
World Health
Assembly
Resolution



Dec 2011

Global
Hepatitis
Programme
created

Nov 2014

Myanmar
National
Hepatitis
Control
Program –

Technical Working Groups of NHCP

National Technical Strategic Group on Viral Hepatitis Prevention and Control

TWG on
Prevention of VH
Transmission

TWG on
Diagnosis,
Clinical Care &
Treatment

TWG on
Health
Work Force
Development

TWG on
Surveillance,
Research &
Strategic
Information

Feb 2015

National Technical
Strategic Group
on Hepatitis
Prevention and
Control is formed

May 2015




Nation-wide
sero-prevalence
survey for
Hep B and C
(DMR and DPH)

June 2015

Finalization of
national
simplified
treatment
guidelines for
Hepatitis C
Infection

Sep 2015

National
Consultation
on
Development
of National
Strategic Plan
on Hepatitis



Prevalence	Population	Prevalence rate
Mono-infection of HBV	* General population (2015)	6.51%
	** Among blood donors (2015)	3.7%
	* Multi-transfused patients	6.1%
	* Patients undergoing haemodialysis	4.9%
	# PWID	8.2%
Mono-infection of HCV	* General population (2015)	2.70%
	** Among blood donors (2015)	0.71%
	* Multi-transfused patients	3.1%
	* Patients undergoing hemodialysis	12.8%
	# PWID	58.9%
Co-infection	# HIV/ HBV	2.2%
	# HIV/ HCV	20.1%
	# HIV & HBV/ HCV	20.7%

* DMR National survey (2015)
IBBS study among PWID (2014)

** Annual report of National Blood Bank (2015)

4 Strategic Directions

Prevention
of
transmission
of Viral
Hepatitis

Diagnosis,
Clinical Care
& Treatment

Workforce
Development

Surveillance,
Research and
Strategic
Information



TOT on
Treatment of
Hepatitis C



Stakeholder's
consultation
meeting on
Action Plan for
Viral Hepatitis
for Myanmar



Meeting of
Update on
Simplified
Treatment
Guidelines
and
Laboratory
Diagnostics
on Viral
Hepatitis



Preparatory
Training Plan
for Hepatitis C
Quick Start
Treatment
Program



Open MRS
Training for
Hepatitis C
Quick Start
Program



Launching
ceremony on
Viral Hepatitis
C Treatment
Program



A new beginning to end hepatitis in Myanmar



HCV Prevalence (all ages) 2.70 % i.e 1,455,223

Adult Viraemic Prevalence 1.88%
i.e.1,004,104 Populations

**Common Genotype is 3(39%) ,
6(49%) and 1(26%)**

Drugs

Daclatasvir (30 mg/60 mg) – donated
by American based BMS through CHAI

Sofosbuvir (400mg) –purchased by the
government budget

Diagnostics

Purchased by the government budget

Program Outline

- Start with treating **total (2,000) Viral Hepatitis 'C'** patients (1,200 mono-infection and 800 HIV co-infection) in June 2017
- **Designated hospitals**

For Mono Infection

- Yangon Speciality Hospital
- North Okkalapa General Hospital
- Nay Pyi Taw 1,000 bedded Hospital (Liver Unit)
- Mandalay General Hospital (Liver Unit)

For Co- infection

- Waibagi Infectious Disease Hospital
- Mingalardon Specialist Hospital
- Tharkata Hospital
- Mandalay General Hospital (Medical Unit)
- Nay Pyi Taw 1,000 bedded Hospital (Medical Unit)

We Have A Long Way To Go

Ways Forward of NHCP

To expand the public sector Hepatitis C treatment program in as phase by phase manner

To set up international procurement and importing mechanism for hepatitis drugs and diagnostics

To start the public sector Hepatitis B treatment program

To strengthen the capacity building on health workforce in public sector for Hepatitis C and B treatment

To conduct operational research in the future in collaboration with DMR, DPH



NOhep... is For All

ELIMINATE HEPATITIS



Let's
in
Myanmar

Fight
against
Hepatitis